Is American Tower Stock Undervalued?
The market action of late has been nothing short of…
Sell
17
HRTS Quote, Financials, Valuation and Earnings
Last price:
$28.94
Seasonality move
:
4.16%
Day range:
$28.89 - $29.61
52-week range:
$28.77 - $36.03
Dividend yield:
0.49%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
16.1K
Avg. volume:
18K
1-year change:
-8.57%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
$28.99 | -- | -- | -- | $0.47 | 0.49% | -- |
|
AGNG
Global X Aging Population ETF
|
$30.10 | -- | -- | -- | $0.15 | 0.83% | -- |
|
CANC
Tema Oncology ETF
|
$24.48 | -- | -- | -- | $0.96 | 2.98% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$29.41 | -- | -- | -- | $0.00 | 0% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$51.91 | -- | -- | -- | $0.33 | 5.43% | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
$24.67 | -- | -- | -- | $0.26 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | 1.482 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 1.018 | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | 1.218 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.470 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.988 | -- | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
-- | -- | -- | -- | -- | -- |
Tema GLP-1, Obesity & Cardiometabolic ETF vs. Competitors
-
Which has Higher Returns HRTS or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Global X Aging Population ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is HRTS or AGNG More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.780, suggesting its less volatile than the S&P 500 by 21.991%.
-
Which is a Better Dividend Stock HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. Global X Aging Population ETF offers a yield of 0.83% to investors and pays a quarterly dividend of $0.15 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns HRTS or CANC?
Tema Oncology ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Tema Oncology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- CANCTema Oncology ETF-- -- -- -
What do Analysts Say About HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Oncology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Tema Oncology ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Tema Oncology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 CANCTema Oncology ETF0 0 0 -
Is HRTS or CANC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Oncology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. Tema Oncology ETF offers a yield of 2.98% to investors and pays a quarterly dividend of $0.96 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Tema Oncology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Tema Oncology ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Tema Oncology ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Tema Oncology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Tema Oncology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- CANCTema Oncology ETF-- -- -- --
-
Which has Higher Returns HRTS or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About HRTS or HTEC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is HRTS or HTEC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.075, suggesting its more volatile than the S&P 500 by 7.497%.
-
Which is a Better Dividend Stock HRTS or HTEC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or HTEC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns HRTS or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About HRTS or JDOC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is HRTS or JDOC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or JDOC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. JPMorgan Healthcare Leaders ETF offers a yield of 5.43% to investors and pays a quarterly dividend of $0.33 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or JDOC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
-
Which has Higher Returns HRTS or MNTL?
Tema Neuroscience and Mental Health ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Tema Neuroscience and Mental Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- MNTLTema Neuroscience and Mental Health ETF-- -- -- -
What do Analysts Say About HRTS or MNTL?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Neuroscience and Mental Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Tema Neuroscience and Mental Health ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Tema Neuroscience and Mental Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 MNTLTema Neuroscience and Mental Health ETF0 0 0 -
Is HRTS or MNTL More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Neuroscience and Mental Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or MNTL?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.49%. Tema Neuroscience and Mental Health ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.26 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Tema Neuroscience and Mental Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or MNTL?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Tema Neuroscience and Mental Health ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Tema Neuroscience and Mental Health ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Tema Neuroscience and Mental Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Tema Neuroscience and Mental Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- MNTLTema Neuroscience and Mental Health ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
